| Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families. | |
| | |
MedLine Citation:
|
PMID: 21850394 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Published studies have reached contradictory conclusions regarding breast cancer risk for women from families segregating a BRCA1 or BRCA2 mutation who do not carry the family-specific mutation. Accurate estimation of breast cancer risk is crucial for appropriate counselling regarding risk management. The aim of this study is to prospectively assess whether breast cancer risk for mutation negative women from families segregating BRCA1 or BRCA2 mutations is greater than for women in the general population. Eligible women were 722 first-, second- and third-degree relatives of a BRCA1 or BRCA2 mutation carrier from 224 mutation positive (128 BRCA1, 96 BRCA2) families, had no personal cancer history at baseline, and had been tested and found not to carry the family-specific mutation. Self-reported family history of cancer, preventive interventions and verified cancer diagnoses were collected at baseline, and every 3 years thereafter. Median follow-up was 6.1 years (range 0.1-12.4 years). Time at risk of breast cancer was censored at cancer diagnosis or risk-reducing surgery. Standardised incidence ratios (SIR) were estimated by comparing observed to population incidences of invasive breast cancer using Australian Cancer Incidence and Mortality Books. Six cases of invasive breast cancer were observed. The estimated SIRs were 1.14 (95% CI: 0.51-2.53) overall (n = 722), 1.29 (95% CI: 0.58-2.88) when restricted to first- and second-degree relatives of an affected mutation carrier (n = 442) and 0.48 (95% CI: 0.12-1.93) when restricted to those with no family history of breast cancer in the non-mutation carrying parental lineage (n = 424). There was no evidence that mutation negative women from families segregating BRCA1 or BRCA2 mutations are at increased risk of breast cancer. Despite this being the largest prospective cohort to assess this issue, moderately increased breast cancer risk (2-fold) cannot be ruled out. |
| | |
Authors:
|
S L Harvey; R L Milne; S A McLachlan; M L Friedlander; K E Birch; P Weideman; ; D Goldgar; J L Hopper; K A Phillips |
Related Documents
:
|
16174894 - Intracerebral hemorrhage: pathophysiology and therapy. 9355054 - Interobserver variability in grading lumbar fusions. 20558124 - Explaining the effects of socio-economic deprivation on survival in a national prospect... 7341334 - Elevated cytostatic activity of monocytes from cancer patients. 12584474 - The use of complementary/preventive medicine to prevent prostate cancer recurrence/prog... 20564744 - The impact of a national program to provide free mammograms to low-income, uninsured wo... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-8-18 |
Journal Detail:
|
Title: Breast cancer research and treatment Volume: - ISSN: 1573-7217 ISO Abbreviation: - Publication Date: 2011 Aug |
Date Detail:
|
Created Date: 2011-8-18 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8111104 Medline TA: Breast Cancer Res Treat Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Division of Cancer Medicine, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Melbourne, VIC, 8006, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Predicting lymphatic drainage patterns and primary tumour location in patients with breast cancer.
Next Document: Iatrogenic displacement of tumor cells to the sentinel node after surgical excision in primary breas...